Purpose of reviewMyeloid malignancies comprise a spectrum of genetically heterogeneous disorders marked by the stepwise acquisition of somatic mutations and clonal evolution. The blood and bone marrow of patients typically consists of a mix of different clones and subclones along the path of clonal evolution that cannot be deconvoluted with most current approaches. Here, we review the application of induced pluripotent stem cell (iPSC) technology to the study of the clonal architecture and clonal evolution of these diseases, focusing on myelodysplastic syndromes and acute myeloid leukemia.Recent findingsReprogramming to pluripotency allows capture of the genomes of single somatic cells into stable iPSC lines. In addition, precise genome editing can introduce specific driver mutations, isolated, and in combinations, into normal iPSCs. Studies utilizing these approaches have elucidated the clonal composition and mutational order in patients with myeloid neoplasms. Importantly, they have also enabled functional interrogation of the cellular and molecular consequences of individual mutations and their combinations and allowed testing of the effects of drugs on distinct disease clones.SummaryHuman iPSCs are important tools to elucidate the mechanisms of progression from normal to malignant haematopoiesis and empower drug testing and drug discovery.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalCurrent Opinion in Hematology
Issue number1
StatePublished - 1 Jan 2021


  • clonal evolution
  • gene editing
  • genotype-To-drug response
  • genotype-To-phenotype
  • reprogramming


Dive into the research topics of 'Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells'. Together they form a unique fingerprint.

Cite this